MedWatch

Orphazyme seeks court protection during restructuring

The biotech company hopes that restructuring will mean that its operations can continue, at least to some degree, paid for through a fundraising round, sale of its assets or a combination of the two.

Photo: Orphazyme / PR

Danish biotech company Orphazyme has applied for legally binding protection from its creditors while it restructures.

The firm hopes that this will mean operations can continue, either partially or entirely, funded by a fundraising round, sale of its assets or a combination of the two, it reports in a stock exchange notification.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs